Maurice Loughrey

Lead Author Colorectal Cancer Reporting Dataset at Royal College of Pathologists

Maurice Loughrey is a Consultant Gastrointestinal Pathologist at Royal Victoria Hospital within the Belfast Trust since February 2005. Maurice has served as the Lead Author for the colorectal cancer reporting dataset at the Royal College of Pathologists since December 2017 and currently holds the position of Honorary Professor of Gastrointestinal Pathology at Queen's University Belfast since July 2023. Additionally, Maurice has been the Pathology Lead for the Bowel Cancer Screening Programme since January 2010. Educational qualifications include an MB BCh BAO in Medicine and a B.Sc. in Medical Genetics from Queen's University Belfast, FRCPath from the Royal College of Pathologists (UK), and a Doctor of Medicine in Molecular Pathology from the University of Melbourne.

Location

Belfast, United Kingdom

Links


Org chart


Teams


Offices

This person is not in any offices


Royal College of Pathologists

1 followers

Pathology is the science at the heart of modern medicine, vital for the diagnosis and clinical management of disease. It is the science behind the cure, or the hidden science that saves lives. Although some pathologists work in laboratories, many work directly with patients in hospitals and the community. Together they are involved in over 70% of all diagnoses, as well as playing an important role in disease prevention, treatment and monitoring. The College is a professional membership organisation committed to setting and maintaining professional standards and to promoting excellence in the practice of pathology. The College aims to advance the science and practice of pathology, to provide public education, to promote research in pathology and to disseminate the results. It is a registered charity. The College was founded in 1962 and received its Royal Charter in 1970. There are 11,000 members worldwide practicing in the 19 pathology specialties. Approximately 78% of the membership are medically qualified, with the remaining 22% being senior clinical scientists.